Introduction to Cardiovascular and Diabetes Medications

Importance of Effective Treatments

Drugs that mitigate cardiovascular issues and diabetes are essential in modern medicine. A recent study known as the ACE Trial investigated the effectiveness of acarbose in diminishing the prevalence of cardiovascular disease and diabetes.

Context of Heart Disease in China

With more than 230 million individuals suffering from heart disease in China, the need for effective medication is paramount. Projections indicate that the number of cardiovascular events in the country could rise by 50% between 2010 and 2030 due to population growth and increased life expectancy.

The Role of Acarbose

Mechanism of Action

Acarbose is an alpha-glucosidase inhibitor that impedes carbohydrate digestion. It has been proposed as a means to lower the incidence of cardiovascular events in patients diagnosed with coronary heart disease.

The Acarbose Cardiovascular Evaluation Trial

To explore the potential of acarbose in reducing cardiovascular events among Chinese patients with established coronary heart disease, impaired glucose tolerance, and type 2 diabetes, the Acarbose Cardiovascular Evaluation trial was initiated. The trial’s findings were recently published in the journal Lancet Diabetes Endocrinology.

The ACE Trial Overview

Study Design and Recruitment

This randomized, double-blind, phase 4 trial included Chinese patients aged 50 years or older who had coronary heart disease and impaired glucose tolerance. The study recruited participants from 176 hospital outpatient clinics throughout China.

Participant Criteria and Treatment

Participants, who had impaired glucose tolerance, a history of myocardial infarction, unstable angina, or stable angina, were randomly assigned to either receive 50 mg of acarbose or a placebo. Prior to the trial, patients were required to have taken at least 80% of a placebo medication and discontinue any other treatments. All participants received lifestyle advice concerning diet, exercise, and smoking cessation. Existing cardiovascular therapies, including blood pressure medications, beta blockers, statins, antiplatelet agents, and renin–angiotensin–aldosterone system inhibitors, were adjusted as necessary to align with international treatment guidelines. The study’s strengths included a robust participant pool and extended follow-up duration in this high-risk demographic.

Results of the Trial

Cardiovascular Outcomes

Contrary to initial expectations, acarbose did not significantly reduce the incidence of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospital admissions for unstable angina, or heart failure.

Impact on Diabetes Incidence

However, the trial revealed that acarbose effectively reduced the risk of developing incidental diabetes by 18%. Researchers suggest that while acarbose did not show a direct impact on cardiovascular outcomes, the possibility of an indirect effect warrants consideration.

Conclusion

The ACE Trial highlights the complexities of treating cardiovascular disease and diabetes, underscoring the importance of ongoing research in this vital area of healthcare.

Author Information

Written by Viola Lanier, PhD, MSc

Reference

Rury R Holman, Ruth L Coleman, Juliana C N Chan, et al. “Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.” Lancet Diabetes Endocrinol. 2017.